ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SVCT Seneca Growth Capital Vct Plc

60.50
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Seneca Growth Capital Vct Plc LSE:SVCT London Ordinary Share GB00BG13MH08 B ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 60.50 59.00 62.00 60.50 60.50 60.50 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Trust,ex Ed,religious,charty -2.26M -2.75M -0.0950 -6.37 17.5M

Seneca Growth Capital VCT plc Update On Omega, Optibiotix And Navs

27/04/2020 6:52pm

UK Regulatory


 
TIDMHYG TIDMSVCT 
 
 
   Seneca Growth Capital VCT Plc (the "Company") 
 
   Partial Realisations of Ordinary Share Investment in Omega Diagnostics 
Group plc ("Omega") and B Share Investment in Optibiotix Health plc 
("Optibiotix"), and updated Ordinary Share and B Share Net Asset Values 
("NAV") 
 
   Partial Realisations of Ordinary Share Investment in Omega and B Share 
Investment in Optibiotix 
 
   Following the recent rise in Omega's share price on AIM, the Company has 
sold a further 543,868 Omega shares realising GBP211,940. The Company 
has now sold a total of 1,693,868 Omega shares from the Ordinary Share 
pool since the year end, realising a total of GBP570,636 and generating 
a profit versus original cost of GBP328,430 (equivalent to an unaudited 
profit of 136%). The Company's Ordinary Share pool retains 600,000 Omega 
shares. 
 
   The Directors are also pleased to report that the Company has sold 
150,000 Optibiotix shares from the B Share pool, realising GBP90,083 and 
generating a profit versus original cost of GBP30,083 (equivalent to an 
unaudited profit of 50%). The Company's B Share pool retains 600,000 
Optibiotix shares. 
 
   New Ordinary Share and B Share Net Asset Values 
 
   The Board have reviewed the carrying value of all Ordinary Share pool 
investments as at 27 April 2020, including Omega at a bid price of 59 
pence per share and Scancell Holdings plc ("Scancell") at a bid price of 
8.0 pence per share, and report that as at 27 April 2020 the unaudited 
NAV per Ordinary share was 35.8 pence per Ordinary share, an increase of 
5.5 pence per Ordinary share from the unaudited NAV of 30.3 pence per 
Ordinary share as at 20 April 2020 (equivalent to an unaudited increase 
of 18.1% over this period). This increase is primarily driven by the 
profit generated on the sale of the Ordinary Share pool's Omega shares, 
and an increase in value of the Ordinary Share pool's remaining Omega 
and Scancell shares, net of the associated movement in the Ordinary 
Share pool performance fee accrual. 
 
   The Board have also reviewed the carrying value of all B Share pool 
investments and report that as at 27 April 2020 the unaudited NAV per B 
share was 89.3 pence per B share, an increase of 9.8 pence per B share 
from the unaudited NAV of 79.5 pence per B share as at 30 March 2020 
(equivalent to an unaudited increase of 12.4% over this period). This 
increase was driven by the profit generated on the sale of the B Share 
pool's Optibiotix shares and an increase in the value of the B Share 
pool's remaining Optibiotix and SkinBiotherapeutics plc shares, net of 
running costs incurred for the period. 
 
   For the purposes of calculating the unaudited NAV per share, quoted 
investments are carried at closing bid prices as at 27 April 2020 and 
unquoted investments are carried at fair value as at 27 April 2020 (fair 
value as determined by the Investment Manager Seneca Partners Limited in 
the case of the B share portfolio, and by the Directors in the case of 
the Ordinary share portfolio). 
 
   The number of B shares in issue at 27 April 2020 was 7,297,020 and the 
number of Ordinary shares was 8,115,376. 
 
   The information above is deemed by the Company to constitute inside 
information as stipulated under the Market Abuse Regulations (EU No. 
596/2014). Upon the publication of this announcement via a Regulatory 
Information Service this inside information is now considered to be in 
the public domain. 
 
   For further information, please contact: 
 
   John Hustler, Seneca Growth Capital VCT Plc at 
https://www.globenewswire.com/Tracker?data=2pj-nhv52Lj56X3j3PlJE9de59sUeHV41XoYHOezAwRpiURT1Mfe1ICOrgjLqXYWvUN6k8AEvS-xzs_BHhHnChkuT17kHv-FDa-6hsYdXwqQmPI3wlWjg2rc8wFdq11N 
john.hustler@btconnect.com 
 
   Richard Manley, Seneca Growth Capital VCT Plc at 
https://www.globenewswire.com/Tracker?data=rebc8-G2p-5W5NOBzy95iIGyAByjBz_Zidkgc0h8gOdbMIeHjTywnvEhlwqlppj25e61_9sHrtk-Xgm7k0ioLvBUupu3q29-7w_HME9Gn0Zn1oYqoyZKX-PKjuTId21vVErhcVs5r55zEIYm3bj9JA== 
Richard.Manley@senecapartners.co.uk 
 
   Any enquiries regarding the offer for subscription of B shares should be 
directed to: 
 
   John Davies at Seneca Partners Limited on 01942 295 981 or at 
https://www.globenewswire.com/Tracker?data=_AYmLIslPQ3Du-8S6lOS4GlVd0jku26PE9-P7PWYYrC8f42Pd-IMA9uNJvSM7l__UutbSw8t7mfeqyTCbP_SvLS35km2Y7RyXChOOgcoIncLnDGdXGV4FvZfgNqxxjEy 
John.Davies@senecapartners.co.uk 
 
 
 
 

(END) Dow Jones Newswires

April 27, 2020 13:52 ET (17:52 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year Seneca Growth Capital Vct Chart

1 Year Seneca Growth Capital Vct Chart

1 Month Seneca Growth Capital Vct Chart

1 Month Seneca Growth Capital Vct Chart

Your Recent History

Delayed Upgrade Clock